Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum. CEO Dan O'Day stated in the press release announcing the numbers, "2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015." Is Gilead Sciences stock a buy after its strongest results in seven years?
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Thank you for attending today's fourth quarter and full year 2022 Gilead Sciences earnings conference call. Just after market closed today, we issued a press release with earnings results for the fourth quarter and full year 2022. The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.